Search

Maravai LifeSciences Holdings Inc (Class A)

Uždarymo kaina

SektoriusSveikatos priežiūra

5.65 -2.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.54

Max

5.77

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-21M

-24M

Pardavimai

-14M

51M

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-47.189

Darbuotojai

435

EBITDA

-17M

-5.2M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+25.43% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-120M

2.2B

Ankstesnė atidarymo kaina

7.9

Ankstesnė uždarymo kaina

5.65

Naujienos nuotaikos

By Acuity

100%

0%

329 / 340 reitingas Healthcare

Maravai LifeSciences Holdings Inc (Class A) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 19:16; UTC

Maravai LifeSciences Holdings Inc. shares are lower, retracing from earlier gains amid broader market concerns over a decline in U.S. retail sales.

2026-08-11 20:01; UTC

Maravai LifeSciences Holdings Inc. shares are lower today, continuing a trend of five consecutive daily declines and trading below the 20-day moving average.

2026-08-10 19:46; UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, but shares are trading lower amid mixed analyst ratings and a continuing decline since Friday.

2026-08-07 20:02; UTC

News

Maravai LifeSciences shares are lower despite Wells Fargo raising the price target to $6.50 following a revenue increase to $51.4 million in Q2.

2026-08-06 23:51; UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

2026-08-03 19:46; UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

2026-07-31 19:36; UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

2026-07-30 16:56; UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

2026-07-29 20:09; UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

2026-07-28 18:06; UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

2026-07-24 19:36; UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

2026-07-23 09:01; UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

2026-07-22 19:56; UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

2026-07-21 19:56; UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

2026-07-20 20:02; UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Akcijų palyginimas

Kainos pokytis

Maravai LifeSciences Holdings Inc (Class A) Prognozė

Kainos tikslas

By TipRanks

25.43% į viršų

12 mėnesių prognozė

Vidutinis 7.25 USD  25.43%

Aukščiausias 8 USD

Žemiausias 6.5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Maravai LifeSciences Holdings Inc (Class A) kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

329 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat